Home Cart Sign in  
Chemical Structure| 113665-84-2 Chemical Structure| 113665-84-2

Structure of Clopidogrel
CAS No.: 113665-84-2

Chemical Structure| 113665-84-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Clopidogrel is an orally active platelet inhibitor targeting the P2Y12 receptor, used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Synonyms: Clopidogrelum

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Clopidogrel

CAS No. :113665-84-2
Formula : C16H16ClNO2S
M.W : 321.82
SMILES Code : O=C(OC)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C=CS3)C2
Synonyms :
Clopidogrelum
MDL No. :MFCD05662337
InChI Key :GKTWGGQPFAXNFI-HNNXBMFYSA-N
Pubchem ID :60606

Safety of Clopidogrel

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Clopidogrel

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 10 µM 24 hours To evaluate the effect of Clopidogrel on intracellular fat deposition in HepG2 cells, results showed that Clopidogrel had no significant effect on intracellular fat deposition. PMC11013111
Bone marrow-derived macrophages (BMDMs) 10 µM 5 days To investigate the effect of clopidogrel on TGF-β1-induced macrophage-to-myofibroblast transition (MMT). Results showed that clopidogrel significantly inhibited P2Y12 expression, MMT, and collagen-matrix production. PMC9481993

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice and IL-1R−/− mice diet-induced obesity model Oral 5 mg/kg single dose To study the anti-platelet and anti-thrombotic effects of Clopidogrel in a diet-induced obesity model, it was found that wild-type DIO mice exhibited resistance to Clopidogrel, while IL-1R?/? DIO mice did not show resistance. PMC7296442
Mice Unilateral ureteral obstruction (UUO) model Oral 60 mg/kg/day Once daily for 7 or 10 days To investigate the therapeutic effect of clopidogrel on renal fibrosis in the UUO model. Results showed that clopidogrel significantly inhibited P2Y12 expression, TGF-β/Smad3 signaling, MMT, and renal fibrosis. PMC9481993
C57BL/6 mice High-fat diet-induced metabolic dysfunction-associated steatotic liver disease model Oral 35 mg/kg/day Once daily for 15 weeks To evaluate the effect of Clopidogrel on a metabolic dysfunction-associated steatotic liver disease model, results showed that Clopidogrel had no significant improvement on steatosis and inflammation. PMC11013111
C57BL/6 mice Photothrombotic stroke model Intraperitoneal injection 40 mg/kg Once daily for 14 days To investigate the impact of Clopidogrel on cognitive and motor function recovery in mice post-stroke. Results showed that Clopidogrel significantly impaired learning and memory recovery, reduced mouse survival rates and body weight, and increased vascular leakage and microglia numbers post-stroke. PMC10380815

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03103685 Dental Diseases|Antiplatelet A... More >>gents|Antiplatelet Drugs Less << PHASE4 UNKNOWN 2018-12-30 -
NCT02054663 Acute Coronary Syndrome PHASE4 COMPLETED 2025-02-15 University of Ottawa Heart Ins... More >>titute, Ottawa, Ontario, K1Y 4W7, Canada Less <<
NCT02707445 Myocardial Ischemia|CLOPIDOGRE... More >>L, POOR METABOLISM of (Disorder) Less << COMPLETED 2025-02-16 -
NCT00360386 Ischemia PHASE2 COMPLETED 2025-02-05 -
NCT02093299 Stroke TERMINATED 2016-11-22 Neurologisk afdeling, Roskilde... More >>, 4000, Denmark Less <<
NCT02185534 Bioequivalence, AUC, Cmax, Pha... More >>rmacokinetics Less << PHASE1 COMPLETED 2025-10-14 Research Site, Berlin, Germany
NCT01012544 Coronary Artery Stent Thrombos... More >>is Less << PHASE4 COMPLETED 2025-12-09 St Antonius Hospital, Nieuwege... More >>in, Utrecht, 3435CM, Netherlands Less <<
NCT01146301 Carotid Stenosis PHASE4 COMPLETED 2025-04-10 St-Antonius Ziekenhuis, Nieuwe... More >>gein, Utrecht, 3435CM, Netherlands Less <<
NCT04501900 Cardiovascular Diseases PHASE4 NOT_YET_RECRUITING 2025-04-26 -
NCT02953405 MCA - Middle Cerebral Artery D... More >>issection Less << UNKNOWN 2025-11-18 SNUBH, Seoul, Korea, Republic ... More >>of Less <<
NCT02391883 Hip Fracture COMPLETED 2025-02-15 -
NCT01159639 Coronary Artery Disease|Aspiri... More >>n Resistance Less << PHASE4 COMPLETED 2025-02-13 Medical school Zagreb, Univers... More >>ity hospital center Zagreb, Zagreb, 10000, Croatia Less <<
NCT00781573 Myocardial Infarction COMPLETED 2014-03-03 Dallas Veterans Hospital, Dall... More >>as, Texas, 75216, United States|The Onassis cardiac Surgery Centre, Athens, Greece|Escorts Health Institute & Research Centre Ltd, New Delhi, India Less <<
NCT06454045 Coronary Artery Disease|Periph... More >>eral Arterial Disease Less << ACTIVE_NOT_RECRUITING 2028-05-13 Heart Institute (InCor) / Univ... More >>ersity of S?o Paulo, S?o Paulo, Sao Paulo, 05403000, Brazil Less <<
NCT03385538 Ischemic Stroke PHASE4 COMPLETED 2017-07-30 Zealand University Hospital, d... More >>ept of neurology, Roskilde, 4000, Denmark Less <<
NCT02711410 Platelet Aggregation Inhibitor... More >>s Less << COMPLETED 2025-10-15 -
NCT00914368 Coronary Artery Disease|Myocar... More >>dial Infarction|Stent Thrombosis|Heart Diseases|Acute Coronary Syndrome Less << PHASE2 COMPLETED 2025-03-10 Uppsala Clinical Research Cent... More >>er, Uppsala, 75185, Sweden Less <<
NCT01129063 Healthy PHASE1 COMPLETED 2025-05-09 Sanofi-Aventis Administrative ... More >>Office, Paris, France Less <<
NCT00799045 Migraine PHASE4 COMPLETED 2025-12-16 Hopital Laval, Quebec, G1V 4G5... More >>, Canada Less <<
NCT01113372 Coronary Artery Disease PHASE4 COMPLETED 2025-07-15 Hospital Anchieta, Brasília, D... More >>F, Brazil|Hospital do Cora??o do Brasil, Brasília, Distrito Federal, Brazil|UNICOR, Linhares, ES, Brazil|Hospital Lifecenter, Belo Horizonte, MG, Brazil|Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil|Universidade Federal do Triangulo Mineiro, Uberaba, MG, Brazil|Instituto do Cora??o do Triangulo Mineiro, Uberlandia, MG, Brazil|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro Integrado de Medicina Intervencionista, Belém, PA, Brazil|Cardiocenter, Jo?o Pessoa, PB, Brazil|Hospital Agamenon Magalh?es, Recife, PE, Brazil|Procape, Recife, PE, Brazil|Funda??o Universitária de Cardiologia, Porto Alegre, RS, Brazil|Hospital M?e de Deus, Porto Alegre, RS, Brazil|Hospital S?o Lucas da PUC, Porto Alegre, RS, Brazil|Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Santa Isabel, Blumenau, SC, Brazil|Instituto de Cardiologia de Santa Catarina, Florianópolis, SC, Brazil|Cardiologia Catanduva, Catanduva, SP, Brazil|Santa Casa de Limeira, Limeira, SP, Brazil|Santa Casa de Marília, Marília, SP, Brazil|INCORPI - Hosp. Fornecedores de Cana, Piracicaba, SP, Brazil|Santa Casa de S?o Carlos, S?o Carlos, SP, Brazil|Hospital Bandeirantes, S?o Paulo, SP, Brazil|Hospital Beneficência Portuguesa, S?o Paulo, SP, Brazil|Hospital Santa Marcelina, S?o Paulo, SP, Brazil|Instituto de Assistencia Médica ao Sevidor Público Estadual- IAMSPE, S?o Paulo, SP, Brazil|EMCOR Emergências do Cora??o, Piracicaba, S?o Paulo - SP, Brazil|Hospital das Clínicas de Ribeir?o Preto, Ribeir?o Preto, S?o Paulo - SP, Brazil|Funda??o Regional de Medicina de S?o José do Rio Preto, S?o José do Rio Preto, S?o Paulo, Brazil|INTERVECENTER Servi?os Cardiovasculares, Palmas, TO, Brazil|Instituto Dante Pazzanese de Cardiologia, S?o Paulo, 04012-180, Brazil Less <<
NCT00174759 Arterial Occlusive Diseases PHASE3 COMPLETED - Sanofi-Aventis, North Ryde, Au... More >>stralia|Sanofi-Aventis, Vienna, Austria|Sanofi-Aventis, Brussels, Belgium|Sanofi-Aventis, Helsinki, Finland|Sanofi-Aventis, Paris, France|Sanofi-Aventis, Berlin, Germany|Sanofi-Aventis, Budapest, Hungary|Sanofi-Aventis, Milan, Italy|Sanofi-Aventis, Gouda, Netherlands|Sanofi-Aventis, Warsaw, Poland|Sanofi-Aventis, Barcelona, Spain|Sanofi-Aventis, Stockholm, Sweden|Sanofi-Aventis, Meyrin, Switzerland|Sanofi-Aventis, Guildford, United Kingdom Less <<
NCT01512485 Healthy PHASE1 COMPLETED 2025-10-06 Anapharm, Sainte-Foy (Quebec),... More >> Canada Less <<
NCT05926271 Acute Coronary Syndrome|CYP2C1... More >>9 Polymorphism Less << PHASE2 RECRUITING 2027-01-15 St. Antonius Hospital, Nieuweg... More >>ein, Utrecht, Netherlands Less <<
NCT01621763 Healthy PHASE1 COMPLETED 2025-09-08 Lambda Therapeutic Research Lt... More >>d, Ahmedabad, Gujrat, India Less <<
NCT01032668 Coronary Artery Disease PHASE3 COMPLETED 2025-12-09 Bursa Yüksek ?htisas E?itim ve... More >> Ara?t?rma Hastanesi, Bursa, 16320, Turkey Less <<
NCT05657041 Coronary Artery Disease|Platel... More >>et Reactivity Less << PHASE2|PHASE3 RECRUITING 2024-11-01 StAntoniusH, Nieuwegein, Utrec... More >>ht, 3435CM, Netherlands|St. Antonius Hospital, Nieuwegein, Netherlands Less <<
NCT00513149 Coronary Artery Disease PHASE4 UNKNOWN 2025-07-11 Division of Cardiology, Depart... More >>ment of Internal Medicine and Department of Medical Imaging, National Taiwan University Hospital, Taipei, 100, Taiwan Less <<
NCT00413608 Healthy PHASE1 COMPLETED 2025-01-09 H?pital Européen Georges Pompi... More >>dou, Paris, 75015, France Less <<
NCT01325935 Coronary Artery Disease PHASE4 COMPLETED 2025-12-13 Asahi General Hospital, Asahi ... More >>City, Chiba, Japan|Kimitsu Chuo Hospital, Kisarazu City, Chiba, Japan|Fukui Cardiovascular Center, Fukui City, Fukui, Japan|Fukuoka City Hospital, Fukuoka City, Fukuoka, Japan|Fukuoka City Medical Association Hospital, Fukuoka City, Fukuoka, Japan|Fukuoka Red Cross Hospital, Fukuoka City, Fukuoka, Japan|University of Occupational and Environmental Health, Kita-Kyushu City, Fukuoka, Japan|National Hospital Organization Fukuoka-Higashi Medical Center, Koga City, Fukuoka, Japan|Gifu Heart Center, Gifu City, Gifu, Japan|Fukuyama City Hospital, Fukuyama City, Hiroshima, Japan|Hiroshima Railway Hospital, Hiroshima City, Hiroshima, Japan|Tsuchiya General Hospital, Hiroshima City, Hiroshima, Japan|Engaru-Kosei General Hospital, Monbetsu-gun, Hokkaido, Japan|Hyogo Prefectural Amagasaki Hospital, Amagasaki City, Hyogo, Japan|Kansai Rosai Hospital, Cardiovascular Center, Amagasaki City, Hyogo, Japan|Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan|Shakaihoken Kobe Central Hospital, Kobe City, Hyogo, Japan|Miki City Hospital, Miki City, Hyogo, Japan|Hyogo College of Medicine, Nishinomiya City, Hyogo, Japan|Meiwa General Hospital, Nishinomiya City, Hyogo, Japan|Hyogo Prefectural Awaji Hospital, Sumoto City, Hyogo, Japan|Kanazawa University Hospital, Kanazawa City, Ishikawa, Japan|Kaisei General Hospital, Sakaide City, Kagawa, Japan|Kagoshima University Hospital, Kagoshima City, Kagoshima, Japan|Tenyoukai Central Hospital, Kagoshima City, Kagoshima, Japan|Ebina General Hospital, Ebina City, Kanagawa, Japan|Fujisawa City Hospital, Fujisawa City, Kanagawa, Japan|Kawasaki Municipal Tama Hospital, Kawasaki City, Kanagawa, Japan|St. Marianna University of Medicine, Toyoko Hospital, Kawasaki City, Kanagawa, Japan|St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan|Synthesis Shinkawahashi Hospital, Kawasaki City, Kanagawa, Japan|Odawara Cardiovascular Hospital, Odawara City, Kanagawa, Japan|Kitazato University School of Medicine, Sagamihara City, Kanagawa, Japan|Sagamihara Kyodo Hospital, Sagamihara City, Kanagawa, Japan|Kanagawa Cardiovascular and Reppiratory Center, Yokohama City, Kanagawa, Japan|Saiseikai Yokohama Tobu Hospital, Yokohama City, Kanagawa, Japan|Showa University Fujigaoka Hospital, Yokohama City, Kanagawa, Japan|St. Marianna University of Medicine, Yokohama City West Hospital, Yokohama City, Kanagawa, Japan|Yokohama City University Hospital, Yokohama City, Kanagawa, Japan|Yokohama City UNiversity Medical Center, Yokohama City, Kanagawa, Japan|Kumamoto Chuo Hospital, Kumamoto City, Kumamoto, Japan|Kumamoto Red Cross Hospital, Kumamoto City, Kumamoto, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto City, Kumamoto, Japan|Saiseikai Kumamoto Hospital, Kumamoto City, Kumamoto, Japan|Sugimura Hospital, Kumamoto City, Kumamoto, Japan|Ijinkai Takeda General Hospital, Kyoto City, Kyoto, Japan|Koseikai Takeda Hospital, Kyoto City, Kyoto, Japan|Kyoto Second Red Cross Hospital, Kyoto City, Kyoto, Japan|Gakken The Holy City Medical Association Hospital, Sagara-gun, Kyoto, Japan|Uji Tokushukai Hospital, Uji City, Kyoto, Japan|Matsuzaka Central General Hospital, Matsuzaka City, Mie, Japan|Suzuka Central General Hospital, Suzuka City, Mie, Japan|Mie Heart Center, Taki-gun, Mie, Japan|Mie University Hospital, Tsu City, Mie, Japan|Nagasaki University Graduate School of Biomedical Science, Nagasaki City, Nagasaki, Japan|Kawasaki Medical School, Kurashiki City, Okayama, Japan|National Hospital Organization Okayama Medical Center, Okayama City, Okayama, Japan|The Sakakibara Heart Institute of Okayama, Okayama City, Okayama, Japan|Ohama Daiichi Hospital, Naha City, Okinawa, Japan|Nakagami Hospital, Okinawa City, Okinawa, Japan|Okinawa Nanbu Tokushukai Hospital, Shimajiri-gun, Okinawa, Japan|Urasoe General Hospital, Urasoe City, Okinawa, Japan|Kawachi General Hospital, Higashi Osaka City, Osaka, Japan|Kansai Medical University Hirakata Hospital, Hirakata City, Osaka, Japan|Kansai Medical University Takii Hospital, Moriguchi City, Osaka, Japan|Komatsu General Hospital, Neyagawa City, Osaka, Japan|Higashi-sumiyoshi Morimoto Hospital, Osaka City, Osaka, Japan|Nissay Hospital, Osaka City, Osaka, Japan|Osaka City General Hospital, Osaka City, Osaka, Japan|Osaka City University, Graduate School of Medicine, Osaka City, Osaka, Japan|Osaka Ekisaikai Hospital, Osaka City, Osaka, Japan|Osaka General Hospital of West Japan Railway Campany, Osaka City, Osaka, Japan|Osaka General Medical Center, Osaka City, Osaka, Japan|Osaka Gyoumeikan Hospital, Osaka City, Osaka, Japan|Osaka Police Hospital, Osaka City, Osaka, Japan|Sakurabashi Watanabe Hospital, Osaka City, Osaka, Japan|Bell Land General Hospital, Sakai City, Osaka, Japan|Mimihara General Hospital, Sakai City, Osaka, Japan|National Cerebral and Cardiovascular Center, Suita City, Osaka, Japan|Osaka University Graduate School of Medicine, Suita City, Osaka, Japan|Saiseikai Senri Hospital, Suita City, Osaka, Japan|Hokusetsu General Hospital, Takatsuki City, Osaka, Japan|Midorigaoka Hospital, Takatsuki City, Osaka, Japan|Department of Cardiovascular Medicine, Saga University, Saga City, Saga, Japan|Mashiko Hospital, Kawaguchi City, Saitama, Japan|Saitama Medical Center, Jichi Medical University, Saitama City, Saitama, Japan|Kusatsu Heart Center, Kusatsu City, Shiga, Japan|Shiga Medical Center for Adults, Moriyama City, Shiga, Japan|Omihachiman Community Medical Center, Omihachiman City, Shiga, Japan|Biwako Ohashi Hospital, Otsu City, Shiga, Japan|Hamamatsu Medical Center, Hamamatsu City, Shizuoka, Japan|Seirei Hamamatsu General Hospital, Hamamatsu City, Shizuoka, Japan|Juntendo University Shizuoka Hospital, Izunokuni City, Shizuoka, Japan|Tokushima Red Cross Hospital, Komatsujima City, Tokushima, Japan|Ayase Heart Hospital, Adachi-ku, Tokyo, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|St. Luke's International Hospital, Chuo-ku, Tokyo, Japan|Sakakibara Heart Institute, Fuchu City, Tokyo, Japan|Tokyo Metroporitan Tama Medical Center, Fuchu City, Tokyo, Japan|Itabashi Chuo Medical Center, Itabashi-ku, Tokyo, Japan|Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan|Teikyo University Hospital, Itabashi-ku, Tokyo, Japan|Tokyo Metroporitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan|Toho University Medical Center Ohashi Hospital, Meguro-ku, Tokyo, Japan|The Cardiovascular Institute, Minato-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|JR Tokyo General Hospital, Shibuya-ku, Tokyo, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan|Tottri University, Yonago City, Tottri, Japan|Shuto General Hospital, Yanai City, Yamaguchi, Japan|Non-profit organization Associations for Establishiment of Evidence in Interventions, Minato-ku, Tokyo, 105-0013, Japan Less <<
NCT01621750 Fasting PHASE1 COMPLETED 2025-09-08 Lambda Therapeutic Research Lt... More >>d, Ahmedabad, Gujrat, India Less <<
NCT00644657 Coronary Artery Disease|Chest ... More >>Pain Less << COMPLETED 2025-09-08 VA Medical Center, 1F187, Okla... More >>homa City, Oklahoma, 73104-5076, United States Less <<
NCT01506713 Fasting PHASE1 COMPLETED 2025-09-06 Anapharm, Sainte-Foy (Quebec),... More >> Canada Less <<
NCT01118793 Coronary Artery Disease COMPLETED 2025-05-10 Scripp Health, La Jolla, Calif... More >>ornia, 92037, United States Less <<
NCT01955642 Brain Ischemia|Ischemic Attack COMPLETED 2025-12-15 CHU de Saint-Etienne, Saint-et... More >>ienne, 42000, France Less <<
NCT00404053 Acute Coronary Syndrome PHASE4 COMPLETED 2025-11-06 -
NCT03667066 Platelet Dysfunction COMPLETED 2018-06-01 Eric Williams Medical Sciences... More >> Complex, Port Of Spain, North, 00000, Trinidad and Tobago Less <<
NCT03329261 Diabetes Mellitus, Type 2|NSTE... More >>MI - Non-ST Segment Elevation MI|Coronary Angioplasty Less << PHASE4 COMPLETED 2019-12-20 HMPIT, Ben Arous, Tunisia
NCT06807788 Takayasu Arteritis (TAK)|Vascu... More >>litis, Systemic Less << ACTIVE_NOT_RECRUITING 2027-10-14 Heart Institute (InCor) / Univ... More >>ersity of S?o Paulo, S?o Paulo, S?o paulo, Brazil Less <<
NCT03006835 Coronary Heart Disease PHASE4 UNKNOWN 2025-12-17 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.11mL

0.62mL

0.31mL

15.54mL

3.11mL

1.55mL

31.07mL

6.21mL

3.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories